ReviewFrontiers in medicine2021
Recent Advances in the Diagnosis, Staging, Treatment, and Prognosis of Advanced Gastric Cancer: A Literature Review.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials.Journal of gastrointestinal cancer · 2025Pooled it
- The efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.Frontiers in immunology · 2025Pooled it
- The Comparison of Short- and Long-Term Outcomes for Laparoscopic Versus Open Gastrectomy for Patients With Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials.Frontiers in oncology · 2022Pooled it
- Value of preoperative peripheral blood inflammation markers in predicting prognosis after radical gastric cancer surgery.Scientific reports · 2026Article
- SASH1 Inhibits Gastric Cancer Progression by Regulating YAP1-Mediated Metabolic Reprogramming.Applied biochemistry and biotechnology · 2026Article
- Biomimetic cancer cell membrane-coated liposomal nanocarriers loaded with silibinin suppress gastric cancer progression via SNHG1/miR-383-5p/HSP90AA1 axis-mediated PI3K/AKT pathway inhibition.Materials today. Bio · 2026Article
- Microbial crosstalk along the oral-gut axis: organ-specific oncogenic adaptations of Porphyromonas gingivalis and Fusobacterium nucleatum.Neoplasia (New York, N.Y.) · 2026Review
- Ferroptosis: The dawn of reversing drug resistance in digestive cancers.Genes & diseases · 2026Review
- Factors Influencing Continuance Intention for Online Consultations Among Survivors of Cancer: Grounded Theory Study.Journal of medical Internet research · 2026Article
- Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions.Frontiers in immunology · 2026Review
- Stage analysis of gastric cancer: a bioinformatic approach.Gastroenterology and hepatology from bed to bench · 2026Article
- Formulation, Optimization and Design of Capecitabine Nanosuspension to Enhance the Anti-Gastric Cancer Efficacy using Box-Behnken Quality-based Design Study.Current drug discovery technologies · 2026Article
- Molecular Imaging in Gastric Cancer: [¹⁸F]FDG and Fibroblast Activation Protein-Targeted PET/CT.Journal of gastric cancer · 2026Review
- Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study.Clinical Medicine Insights. Oncology · 2026Article
- The impact of the COVID-19 pandemic on the diagnosis and surgical treatment processes of gastric cancer.Turkish journal of surgery · 2025Article
- Unsupervised machine learning reveals prognostic value of dynamic carbohydrate antigen 125 trajectory in gastric cancer.BMC cancer · 2025Article
- Stomach Cancer Incidence in Asians as Compared to Other Ethnic Populations Over Time from 2000 to 2021 in SEER Areas of the United States.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Biomembrane-coated nanosystems as next-generation delivery systems for the treatment of gastrointestinal cancers.Bioengineering & translational medicine · 2025Review
- A hybrid multi-instance learning-based identification of gastric adenocarcinoma differentiation on whole-slide images.Biomedical engineering online · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the most common cause of cancer related deaths worldwide which results in malignant tumors in the digestive tract. The only radical treatment option available is surgical resection. Recently, the implementation of neoadjuvant chemotherapy resulted in 5-year survival rates of 95% for early gastric cancer. The main reason of treatment failure is that early diagnosis is minimal, with many patients presenting advanced stages. Hence, the greatest benefit of radical resection is missed. Consequently, the main therapeutic approach for advanced gastric cancer is combined surgery with neoadjuvant chemotherapy, targeted therapy, or immunotherapy. In this review, we will discuss the various treatment options for advanced gastric cancer. Clinical practice and clinical research is the most practical way of reaching new advents in terms of patients' characteristics, optimum drug choice, and better prognosis. With the recent advances in gastric cancer diagnosis, staging, treatment, and prognosis, we are evident that the improvement of survival in this patient population is just a matter of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.